Table 2.
Main baseline characteristics among patients with type 2 diabetes mellitus of each study included in the systematic review
|
Ref.
|
Groups
|
Males/Females (n)
|
Year after diagnosis
|
Age (yr)
|
Weight (kg)
|
Height (cm)
|
BMI (kg/m2)
|
HbA1C (%)
|
| Balducci et al[20], 2012 | HI (n = 152); LI (n = 136) | 91/61; 83/53 | 7.8 ± 6.2; 5.9 ± 4.0 | 59.5 ± 8.3; 58.4 ± 8.9 | NA | NA | 31.2 ± 4.6; 31.9 ± 4.7 | 7.24 ± 1.39; 6.99 ± 1.39 |
| Terada et al[21], 2013 | HIIT (n = 7); MICT (n = 8) | 4/4; 4/3 | 6 ± 4; 8 ± 4 | 62 ± 3; 63 ± 5 | 80.5 ± 9.9; 93.9 ± 18.3 | NA | 28.4 ± 4.1; 33.1 ± 4.5 | 6.6 ± 0.6; 6.7 ± 0.6 |
| Karstoft et al[22], 2013 | HIIT (n = 12); MICT (n = 12); CON (n = 8) | 7/5; 8/4; 5/3 | 3.5 ± 0.7; 6.2 ± 1.5; 4.5 ± 1.5 | 57.5 ± 2.4; 60.8 ± 2.2; 57.1 ± 3 | 84.9 ± 4.9; 88.2 ± 4.7; 88.5 ± 4.7 | NA | 29.0 ± 1.3; 29.9 ± 1.6; 29.7 ± 1.9 | 6.9 ± 0.2; 6.6 ± 0.2; 6.4 ± 0.2 |
| Mitranun et al[23], 2014 | HIIT (n = 14); MICT (n = 14); CON (n = 15) | 5/9; 5/9; 5/10 | 19.5 ± 0.4; 20.5 ± 0.4; 21.1 ± 0.6 | 61.2 ± 2.8; 61.7 ± 2.7; 60.9 ± 2.4 | 66.5 ± 3.7; 65.8 ± 3.1; 67.7 ± 3.2 | 149 ± 4; 149 ± 5; 152 ± 5 | 29.6 ± 0.5; 29.4 ± 0.7; 29.7 ± 0.4 | 60 ± 2a; 61 ± 2a; 62 ± 2a |
| Hollekim-Strand et al[24], 2014 | HIIT (n = 20); MICT (n = 17) | 12/8; 11/6 | 4.2 ± 2.3; 3 ± 2.6 | 58.6 ± 5; 54.7 ± 5.3 | NA | NA | 30.2 ± 2.8; 29.7 ± 3.7 | 7.0 ± 1.2; 6.7 ± 0.7 |
| Winding et al[25], 2018 | HIIT (n = 13); END (n = 12); CON (n = 7) | 7/6; 7/5; 5/2 | 8 ± 4; 6 ± 4;7 ± 5 | 54 ± 6; 58 ± 8; 57 ± 7 | 84.2 ± 11.1; 82.1 ± 13.7; 87.7 ± 11.3 | NA | 28.1 ± 3.5; 27.4 ± 3.1; 28.0 ± 3.5 | 6.8 ± 0.8; 6.9 ± 0.9; 7.0 ± 1.2 |
| Hwang et al[26], 2019 | HIIT (n = 23); MICT (n = 19); CON (n = 16) | 11/12; 11/8; 8/8 | 7.8 ± 1.3; 8.3 ± 1.5; 8.2 ± 1.5 | 65 ± 2; 62 ± 2; 61 ± 2 | 92.0 ± 4.7; 92.6 ± 4.5; 91.5 ± 3.9 | 170 ± 3; 170 ± 3; 164 ± 2 | 31.7 ± 1.3; 31.8 ± 1.4; 33.9 ± 1.4 | 7.1 ± 0.3; 7.2 ± 0.3; 7.4 ± 0.4 |
| Suryanegara et al[27], 2019 | HIIT (n = 13); CON (n = 13) | 3/10; 3/10 | 4.8 ± 1.2; 4.3 ± 1.4 | 61.1 ± 8.6; 59.8 ± 8.6 | 90.5 ± 15.0; 91.0 ± 9.8 | 170.4 ± 7.6; 169.8 ± 8.6 | 31.3 ± 5.4; 31.9 ± 5.3 | 53.6 ± 10.5a; 55.5 ± 6.0a |
| Mortensen et al[28], 2019 | HIIT (n = 11); END (n = 10) | 6/5; 7/3 | 7 ± 4; 5 ± 4 | 53 ± 7; 57 ± 9 | 85 ± 12; 86 ± 11 | NA | NA | 6.8 ± 0.9; 6.9 ± 0.9 |
| Baasch-Skytte et al[29], 2020 | 10-20-30 (n = 23); MICT (n = 21) | 23/0; 21/0 | 8.0 ± 5.9; 7.0 ± 5.7 | 61.0 ± 6.2; 61.2 ± 7.1 | 101.9 ± 22.8; 100.3 ± 13.8 | 181.5 ± 6.5; 180.4 ± 7.2 | 30.6 ± 5.4; 30.7 ± 4.4 | 7.5 ± 1.6; 7.3 ± 1.1 |
| Gildea et al[30], 2021 | HIIT (n = 9); MICT (n = 10); CON (n = 9) | 6/3; 7/3; 4/5 | 6.6 ± 3.5; 6.4 ± 3.8; 6.6 ± 3.3 | 52 ± 10; 53 ± 10; 54 ± 9 | 92.0 ± 4.7; 92.6 ± 4.5; 91.5 ± 3.9 | NA | 28.7 ± 3.0; 30.0 ± 5.7; 30.5 ± 3.6 | 7.3 ± 0.5; 6.9 ± 0.5; 6.8 ± 1.0 |
| Li et al[31], 2022 | HIIT (n = 13); MICT (n = 12); CON (n = 12) | 13/0; 12/0; 12/0 | 1.95 ± 0.55; 1.79 ± 0.52; 1.84 ± 0.49 | 38 ± 6; 39 ± 5; 40 ± 7 | 75 ± 9.98; 73.1 ± 7.8; 71.76 ± 9.7 | 166.9 ± 6.25; 165.8 ± 5.56; 166.7 ± 6.86 | 27.4 ± 5.5; 26.8 ± 4.2; 26.5 ± 5.0 | 7.2 ± 0.5; 7.02 ± 0.44; 7.06 ± 0.38 |
a
Expressed in mmol/moL. CON: Control group; NA: Not available; HIIT: High-intensity interval training; HI: Moderate-to-high intensity; MICT: Moderate intensity continuous training; END: Endurance training; LI: Low-to-moderate intensity.